683240-81-5

Basic information

• Product Name: 2H-Benzimidazol-2-one,5-chloro-1,3-dihydro-6-methyl-(9CI)
• Synonyms: 2H-Benzimidazol-2-one,5-chloro-1,3-dihydro-6-methyl-(9CI);5-Chloro-6-methyl-1H-benzo[d]imidazol-2(3H)-one;5-Chloro-6-methylbenzoimidazol-2-one
• CAS NO: 683240-81-5
• Molecular Formula: C8H7ClN2O
• Molecular Weight: 182.61
• Product Categories: BENZIMIDAZOLE
• Mol File: 683240-81-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Room temperature.
• CAS DataBase Reference: 2H-Benzimidazol-2-one,5-chloro-1,3-dihydro-6-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Benzimidazol-2-one,5-chloro-1,3-dihydro-6-methyl-(9CI)(683240-81-5)
• EPA Substance Registry System: 2H-Benzimidazol-2-one,5-chloro-1,3-dihydro-6-methyl-(9CI)(683240-81-5)

Safety Data

• Hazardous Substances Data: 683240-81-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2H-Benzimidazol-2-one,5-chloro-1,3-dihydro-6-methyl-(9CI) is used as a chemical intermediate in the synthesis of various pharmaceuticals. Its unique structure and properties make it a valuable component in the development of new drugs, particularly those targeting a range of diseases.
Used in Agrochemical Industry:
In addition to its pharmaceutical applications, 2H-Benzimidazol-2-one,5-chloro-1,3-dihydro-6-methyl-(9CI) is also utilized as an intermediate in the production of agrochemical products. Its potential role in this industry highlights its versatility and the broad scope of its applications in different fields.

Upstream product

• 63155-04-4 4-chloro-5-methylbenzene-1,2-diamine 
• 530-62-1 1,1'-carbonyldiimidazole 

Relevant articles and documents

Biological characterization of new inhibitors of microsomal PGE synthase-1 in preclinical models of inflammation and vascular tone

Background and Purpose: Microsomal PGE synthase-1 (mPGES-1), the inducible synthase that catalyses the terminal step in PGE2 biosynthesis, is of high interest as therapeutic target to treat inflammation. Inhibition of mPGES-1 is suggested to be safer than traditional NSAIDs, and recent data demonstrate anti-constrictive effects on vascular tone, indicating new therapeutic opportunities. However, there is a lack of potent mPGES-1 inhibitors lacking interspecies differences for conducting in vivo studies in relevant preclinical disease models. Experimental Approach: Potency was determined based on the reduction of PGE2 formation in recombinant enzyme assays, cellular assay, human whole blood assay, and air pouch mouse model. Anti-inflammatory properties were assessed by acute paw swelling in a paw oedema rat model. Effect on vascular tone was determined with human ex vivo wire myography. Key Results: We report five new mPGES-1 inhibitors (named 934, 117, 118, 322, and 323) that selectively inhibit recombinant human and rat mPGES-1 with IC50 values of 10–29 and 67–250 nM respectively. The compounds inhibited PGE2 production in a cellular assay (IC50 values 0.15–0.82 μM) and in a human whole blood assay (IC50 values 3.3–8.7 μM). Moreover, the compounds blocked PGE2 formation in an air pouch mouse model and reduced acute paw swelling in a paw oedema rat model. Human ex vivo wire myography analysis showed reduced adrenergic vasoconstriction after incubation with the compounds. Conclusion and Implications: These mPGES-1 inhibitors can be used as refined tools in further investigations of the role of mPGES-1 in inflammation and microvascular disease.

NOVEL PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGES-1 INHIBITORS

The compounds 1-(5-chloro-6-methyl-1-(6-(trifluoromethyl)pyridin-2-yl)-1H-benzo[d]imidazol- 2-yl)-N-((3S,4R)-4-hydroxytetrahydrofuran-3-yl)piperidine-4-carboxamide and l-(6-chloro-5- methy1-1-(6-(trifluoromethyl)pyridin-2-yl)-1H-benzo[d]imidazol-2-yl)-N-((3S,4R)-4- hydroxytetrahydrofuran-3-yl)piperidine-4-carboxamide, as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising any one of these compounds. The compound are useful for the treatment and/or prevention of a disorder selected from an inflammatory disease; an autoimmune disease; pain; a breathing disorder; cancer; a cardiovascular disease; a neurodegenerative disease; a bone disease; a disorder due to familial adenomatous polyposis (FAP) condition; overactive bladder; fever; and inflammation-related anorexia.

PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGE-1 INHIBITORS

The compounds (R)-1-(5-chloro-6-methyl-1-(6-(trifluoromethyl)pyridin-2-yl)-1H- benzo[d]imidazol-2-yl)-N-(tetrahydrofuran-3-yl)piperidine-4-carboxamide and (R)-1-(6-chloro- -methyl-1-(6-(trifluoromethyl)pyridin-2-yl)-1H-benzo[d]imidazol-2-yl)-N-(tetrahydrofuran-3- yl)piperidine-4-carboxamide, as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising any one of thesecompounds. The compoundsareuseful for the treatmentand/or preventionof a disorder selected from an inflammatory disease; an autoimmune disease; pain; a breathing disorder; cancer; a cardiovascular disease; a neurodegenerative disease; a bone disease; a disorder due to familial adenomatous polyposis (FAP) condition; overactive bladder; fever; and inflammation-related anorexia.

PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGES-1 INIHIBITORS

A compound of formula (I) as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compound. The compound is useful for the treatment of disorder selected from inflammatory diseases, pain, auto-immune disease, breathing disorders, fever, cancer, inflammation related anorexia, overactive bladder, familial adenomatous polyposis (FAP) condition, neurodegenerative diseases, bone diseases and cardiovascular diseases.

MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS

A compound of formula (I): as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compound. The compound is useful for the treatment of disorder selected from inflammatory diseases, nociceptive pain, auto-imm

BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS

Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.